4th European Congress of Neurology and Neuropsychiatry

PARIS - Oct. 7, 2025 - PRLog -- Source: Organizing Committee, 4th European Congress of Neurology and Neuropsychiatry (Neuro 2026)
Location: Paris, France
Website: https://neurologyconf.com/

The field of neurology continues to evolve rapidly, with 2025 marking a turning point in the fight against neurodegenerative and psychiatric disorders. From nanotechnology-driven.

Below are five of the most significant global breakthroughs shaping neuroscience today:

1. Nanotechnology Reverses Alzheimer's Symptoms in Mice

A team of international researchers has successfully used bioactive nanoparticles to repair the blood-brain barrier and reduce amyloid-beta accumulation — the key pathological driver of Alzheimer's disease.
🔗 Reference: New York Post (https://nypost.com/2025/10/06/health/nanotech-used-to-reverse-alzheimers-disease-in-mice-study/?utm_source=chatgpt.com)

2. EU Approves Leqembi for Early-Stage Alzheimer's

In a milestone for neurotherapeutics, the European Commission has granted marketing authorization for Leqembi (lecanemab), developed by Eisai and Biogen, to treat patients in early stages of Alzheimer's disease.
🔗 Reference: Reuters (https://www.reuters.com/business/healthcare-pharmaceutica...)

3. Deep Brain Stimulation Reduces Anxiety in Parkinson's Disease

A study published earlier this year identified distinct brain wave signatures linked to anxiety among Parkinson's disease patients.
🔗 Reference: The Guardian (https://www.theguardian.com/society/2025/feb/24/deep-brai...)

4. Sanofi Acquires Vigil Neuroscience in $470 Million Alzheimer's Deal

Pharma giant Sanofi has announced the acquisition of Vigil Neuroscience, securing access to the promising Alzheimer's drug candidate VG-3927, which targets TREM2 — a key microglial receptor involved in neuroinflammation.
The merger underscores Sanofi's strategic commitment to developing next-generation neuroprotective therapies.
🔗 Reference: Wall Street Journal (https://www.wsj.com/health/pharma/sanofi-to-buy-vigil-neuroscience-for-about-470-million-a65f2d4a?utm_source=chatgpt.com)

5. FDA Approves Self-Injectable Alzheimer's Drug "Leqembi Iqlik"

In a major step toward patient-centered care, the U.S. Food and Drug Administration has approved Leqembi Iqlik, a self-injectable version of the Alzheimer's drug Leqembi..
🔗 Reference: TIME Magazine (https://time.com/7314266/alzheimers-drug-injectable-leqembi/?utm_source=chatgpt.com)

A New Era of Neuroinnovation

"These developments mark an extraordinary leap forward for neuroscience," said Dr. Allal Boutajangout, President of Neuro 2026 and Research Professor at NYU Langone Health.
"From early detection to personalized treatment, we are entering a period of rapid transformation in understanding and managing brain diseases."

The 4th European Congress of Neurology and Neuropsychiatry (Neuro 2026)—scheduled for February 23–24, 2026, in Paris, France—will showcase these pioneering discoveries and host in-depth discussions with global experts in neurology, psychiatry, and brain science.

Conference Quick Links:

🌐 Official Website: https://neurologyconf.com/
🧩 Abstract Submission: https://neurologyconf.com/abstract/
📝 Registration: https://neurologyconf.com/registration/

For media inquiries, partnerships, or participation details, please contact:
📧 info@neurologyconf.com | 📞 WhatsApp: +44 7378558315